Business Context and Reporting Period
This Form 8-K filing by Alnylam Pharmaceuticals, Inc. (ALNY) reports corporate governance events and the results of the Annual Meeting of Stockholders. The report date is May 27, 2026, covering events occurring as of May 20, 2026, and the Annual Meeting held on March 25, 2026.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and shareholder voting results.
Material Changes and Corporate Actions
Board Expansion and Appointment
- The Board of Directors expanded from ten to eleven members, effective June 1, 2026.
- Benjamin F. Cravatt, Ph.D., was elected as a Class III director with a term expiring in 2028.
- Dr. Cravatt will serve on the Science and Technology Committee.
Director Compensation
- Annual Cash Retainer: $75,000.
- Initial Equity Grant: A stock option with a grant date fair value of $600,000, vesting in three equal tranches over three years.
- Future Annual Equity: Eligible for standard annual awards (currently $200,000 in RSUs and $200,000 in stock options for non-employee directors).
Annual Meeting Voting Results
As of the record date (March 25, 2026), 133,427,910 shares were outstanding. Key voting outcomes included:
- Director Elections (Class I):
- Stuart A. Arbuckle: 86.4% For
- Yvonne L. Greenstreet, M.D.: 96.1% For
- Elliott Sigal, M.D., Ph.D.: 83.6% For (notable dissent with 12.8M votes against)
- Executive Compensation (Say-on-Pay): Approved with 92.9% For votes.
- Auditor Ratification: PricewaterhouseCoopers LLP ratified with 95.4% For votes.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on business outlook, or specific risk factors. It is a standard disclosure of governance changes and meeting results.
Investor Verification Checklist
- Verify the impact of the new board member, Dr. Cravatt, on the Science and Technology Committee's strategic direction.
- Review the significant number of votes cast against Elliott Sigal (12.8 million) to understand shareholder sentiment regarding his tenure.
- Confirm the total equity compensation expense impact of the new director's $600,000 initial grant in future quarterly filings.
- Check subsequent filings for the formal appointment of PricewaterhouseCoopers LLP for the fiscal year ending December 31, 2026.